Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2018 Archives
Dec 11, 2018 --Company Expects to be Well within Its Financial Covenants through the Maturity Date of the Term A Loans-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an amendment of its credit agreement effecting the term A loans thereunder (Term A Loans) to provide the company greater... More |
Dec 5, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2018 Prescription for Success Healthcare Conference on December 12, 2018 at 2:40 p.m.... More |
Nov 12, 2018 --Lannett Locks in $50 Million of Gross Profit for 16-Week Period-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. (Amneal) with regard to Levothyroxine Sodium Tablets USP. Under the... More |
Nov 7, 2018 - Fiscal 2019 First Quarter Net Sales and Adjusted Net Income Ahead of Expectations Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 first quarter ended September 30, 2018. "For the fiscal 2019 first quarter, net sales and adjusted net income... More |
Nov 7, 2018 Product Launches, Cost Savings
|
Nov 6, 2018 --Company Has Commenced Launch of Clarithromycin and Expects to Begin Marketing Entacapone In Early Calendar Year 2019-- Lannett Company, Inc. (NYSE: LCI) today announced that it has expanded its agreement with Sunshine Lake LLC, the U.S. subsidiary of the HEC Pharm Group (HEC) of China, to be the exclusive... More |
Nov 1, 2018 --Launch Commenced; First-Time Generic Launch of Levitra®-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Rivopharm SA to be the exclusive U.S. distributor of Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10... More |
Nov 1, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 first quarter on Wednesday, November 7, 2018, after the market closes. Lannett... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Adare Pharmaceuticals, Inc., to be the exclusive U.S. distributor of Dexmethylphenidate Hydrochloride... More |
Oct 8, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it has engaged and/or expanded the role of existing advisors to assist in evaluating a range of alternatives regarding the company's debt and... More |
Oct 1, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it commenced marketing five new products in its recently completed fiscal 2019 first quarter, bringing to 12 the total number of products... More |
Aug 28, 2018 Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 fourth quarter and full year ended June 30, 2018. "For both the fiscal 2018 fourth quarter and full year, our... More |
Aug 22, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 fourth quarter and full year on Tuesday, August 28, 2018, after the market closes.... More |
Aug 20, 2018 --Company Announces Preliminary Fiscal 2018 Fourth-Quarter and Full-Year Financial Results; To Host Conference Call Today at 8 a.m. ET-- Lannett Company, Inc. (NYSE: LCI) today said that its distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which expires on March 23, 2019, will not be renewed. "The Steinlauf family... More |
Aug 3, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive perpetual licensing agreement with Andor Pharmaceuticals, LLC for Methylphenidate Hydrochloride Extended... More |
Jul 23, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it launched four products in June 2018, bringing to seven the total number of products launched since January 1, 2018. The June product... More |
Jun 29, 2018 Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost reduction plan of its subsidiary, Cody Laboratories (Cody), a developer and manufacturer of pain management active... More |
Jun 1, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Levofloxacin Oral... More |
May 21, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dronabinol Capsules... More |
May 7, 2018 --Adjusted EPS Higher Than Expected; Outlook for Fiscal 2018 Net Sales and Adjusted Profitability Affirmed-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 third quarter ended March 31, 2018. "We continue to make good progress executing on our strategic... More |
May 7, 2018 --Transaction Includes 23 Approved and 1 Pending Drug Product Applications, Primarily Oral Solutions-- Lannett Company, Inc. (NYSE: LCI) today announced that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International plc for an upfront payment plus... More |
May 3, 2018 Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Deutsche Bank 43rd Annual Health Care Conference at 9:20 a.m. ET, on... More |
May 2, 2018 Lannett To Report Fiscal 2018 Third-Quarter Financial Results, Host Conference Call On Monday, May 7 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 third quarter on Monday, May 7, 2018, after the market closes. Lannett management will... More |
Apr 30, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that effective July 1, 2018 current director, Patrick LePore, will become chairman of the board of directors, succeeding Jeffrey Farber, who will... More |
Apr 20, 2018 --Company Re-aligns Management Responsibilities-- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Maureen M. Cavanaugh to the newly created position, senior vice president and chief commercial operations officer, effective... More |
| 1-25 26-33 |